With some medical interventions, immunogenicity is the whole point—hence the “good” immunogenicity provoked by vaccines. Immunogenicity is much to be avoided, however, when biotherapeutics are ...

With drug development costs increasing, it is now critical for the biopharmaceutical industry to focus its efforts on identifying new technologies and methods that can predict the efficacy and safety ...

The first patents of recombinant-DNA-derived biopharmaceuticals will expire in the near future, which should allow the marketing of 'generics'. With classical drugs, generics can be marketed on the ...

Determining the safety and efficacy of biotherapeutics is a key part of the drug development process. There is a need to develop assays that accurately and reliably detect and quantify immune ...

SAN DIEGO, Dec. 19, 2023 /PRNewswire/ -- Abzena, the leading end-to-end CDMO for complex biologics and bioconjugates, has co-authored a publication with the US Food and Drug Administration (FDA) ...

Serum samples for anti-panitumumab antibody testing were collected from mCRC patients enrolled in 4 panitumumab clinical trials (20050184, 20060277, 20050181, and 20050203). Patients in these studies ...

This article is based on a poster originally authored by Ebru Aydin Kurtulmus, Dagmar Hildebrand, Fiordiligie Casilag, Verena Banschbach, Jessica Heckmann, Sarah Schott, Marc Botcherby and Volker ...

From the 1980s, therapeutic protein drugs — monoclonal antibodies, proteins, antibody-drug conjugates, bispecific antibodies, etc. — have been widely employed in the treatment of HIV, tumors and other ...

Boca Raton, Florida, April 23, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s ...

Determining the safety and efficacy of biotherapeutics is a key part of the drug development process. There is a need to develop assays that accurately and reliably detect and quantify immune ...